Clinical trial / 2015
Adjunctive crocin improved depression, anxiety, and general health scores in depressed patients.
A four-week randomized, double-blind, placebo-controlled trial tested crocin tablets (30 mg/day) alongside SSRI therapy in 40 patients with major depressive disorder. The crocin group demonstrated significantly greater decreases in Beck Depression Inventory (17.6 vs. 6.15), Beck Anxiety Inventory (12.7 vs. 2.6), and General Health Questionnaire scores (17.2 vs. 10.3) compared to placebo (p < 0.0001). Limitations included a brief intervention period, modest sample size, and dependence on self-reported evaluations.
- Study type
- Randomized double-blind placebo-controlled trial
- Who was studied
- 40 adults aged 24-50 with major depressive disorder, Iran
- What was measured
- Depression, anxiety, and general health scores
THE PAPER
Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. J Affect Disord, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.